#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Is Obesity a Universal Phenotype in Children with Type 2 Diabetes?

What is the global prevalence of obesity in children and adolescents suffering from type 2 diabetes mellitus (T2DM)? Does the occurrence of obesity in pediatric T2DM correlate with gender or race? And how is obesity in T2DM under 18 years of age associated with glycemic control and dyslipidemia? These questions have been addressed by Canadian authors in their recently published systematic review and meta-analysis, which deals with various issues related to childhood obesity.
Source: Modern Treatment of Diabetes 19. 4. 2023

News Economic Burden and Loss of Quality of Life as a Consequence of Dry Eye Syndrome

Canadian authors evaluated the direct and indirect financial costs associated with dry eye syndrome (DED − dry eye disease) and the impact of this condition on the quality of life (QoL) of patients. The results were stratified according to the severity of the condition. The most significant was the loss of work productivity, highlighting the need for adequate solutions for DED.
Source: Treatment of Glaucoma 1. 4. 2024

News Benefit of Empagliflozin in Patients with Chronic Kidney Disease – Results of the EMPA-KIDNEY Study

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type 2 diabetes mellitus (T2DM) and chronic heart failure regardless of ejection fraction value. Its impact on renal function and the prognosis of patients with chronic kidney disease (CKD) irrespective of the presence of T2DM was specifically evaluated in the double-blind placebo-controlled EMPA-KIDNEY study.
Source: Diabetes 18. 10. 2023

News Teriflunomide vs. Dimethyl Fumarate: Does Their Classification into Different Treatment Lines Have Merit?

Teriflunomide is one of the first-choice medications in the treatment of multiple sclerosis (MS) patients, not only in the Czech Republic. Conversely, the use of dimethyl fumarate is more limited here compared to other countries. Did the data from real-world clinical practice published this year actually demonstrate differences in the efficacy of both medications, and thus justify their classification?
Source: Multiple Sclerosis 4. 1. 2023

Journal articles Hodgkin´s Lymhoma – the Treatment Aproaches Development and Current Trends

Author of the article: J. Kořen, M. Trněný Source: Klinická onkologie | Supplementum 3/2015 19. 10. 2015

News Li-Fraumeni Syndrome – Indication for Testing and Recommended Surveillance

A germline mutation of the TP53 gene, which causes Li-Fraumeni syndrome, results in a congenital predisposition to the occurrence of malignant tumors, such as pediatric malignancies, breast cancer, bone sarcomas, and others. We bring a summary of indications for testing the pathogenic variant of the TP53 gene according to the recommendations of the National Comprehensive Cancer Network (NCCN) and the surveillance program for carriers of this variant according to the consensus of the current recommendations of the European, American, Japanese, and Australian scientific societies compared to the recommendations of the Czech Oncology Society ČLS JEP.
Source: Genetics 3. 5. 2023

News Desirable Side Effects of Antidiabetics

The days when diabetology was a field solely focused on normalizing blood sugar levels are long gone. Today, the approach in diabetology increasingly prioritizes influencing the patient's overall life prognosis, particularly reducing cardiovascular risk. What can be the desirable side effects of the main groups of antidiabetics that are not related to merely lowering glucose levels?
Source: Diabetes 6. 11. 2020

News Impact of Comorbidities on the Efficacy of Ceftaroline Fosamil in Complicated Skin and Soft Tissue Infections − Pooled Analysis of 3 Studies

In 3 randomized Phase III studies, ceftaroline fosamil demonstrated non-inferiority in treating complicated skin and soft tissue infections (cSSTI) compared to vancomycin + aztreonam. A recent pooled analysis of these 3 studies evaluated the impact of age and comorbidities on clinical outcomes.
Source: Anti-Infectives 17. 3. 2023

News The Importance of Vitamin D for the Proper Function of the Immune System

The relationship between vitamin D and the immune system has been known for nearly 30 years, but only in recent years have we gained new insights that explain and further refine the physiological role of vitamin D in the functioning of the human immune system.
Source: GI, colic and microbiome 29. 3. 2021

Journal articles Ovarian epithelial malignant tumors in adolescence

Author of the article: Luboš Minář, Z. Ivanová, E. Jandáková Source: Česká gynekologie | 2/2014 21. 4. 2014

News Experience from Clinical Practice with Intestinal Gel LECIG in Treating Parkinson's Disease

A Swedish observational study evaluated the applicability of the LECIG intestinal gel, which contains levodopa (20 mg/ml), carbidopa (5 mg/ml), and entacapone (20 mg/ml), in clinical practice for patients with Parkinson's disease.
Source: Parkinson's Disease 12. 5. 2022

News Bimekizumab in the Treatment of Psoriasis After Failure of (Not Only) Anti-IL-17A Antibodies – Case Reports

German authors last year described the first 2 cases of patients with psoriasis in whom treatment with, among other things, anti-IL-17A antibodies failed, but who responded to the blockade of interleukins IL-17A/IL-17F with bimekizumab after its approval by the European Medicines Agency (EMA).
Source: Psoriasis 2. 4. 2023

News Neutropenia with Thrombocytopenia after Alemtuzumab? − Case Report

Early neutropenia with thrombocytopenia is not a common side effect of alemtuzumab. However, the patient in the following case report by Italian colleagues was affected. What was the outcome?
Source: Multiple Sclerosis 1. 11. 2023

News New Alternative in the Treatment of Diffuse Large B-cell Lymphoma

For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not suitable candidates for autologous stem cell transplantation, a wide range of treatment regimens is available. Recently, the addition of polatuzumab vedotin to rituximab and bendamustine therapy has shown promising efficacy in both registration studies and real-world clinical practice.
Source: Non-Hodgkin Lymphomas and CLL 4. 1. 2021

News Ixekizumab is a Safe Option for Long-Term Treatment of Inflammatory Diseases

Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) are chronic inflammatory diseases that often require long-term treatment. The current pharmacotherapy of these diseases includes conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and targeted biological therapies that inhibit the effects of tumor necrosis factor (TNF) or interleukins IL-23 and IL-17. An analysis published in early 2020 in the journal Rheumatology focused on the safety of long-term inhibition of IL-17A using ixekizumab.
Source: Biological Treatment 26. 10. 2020

News Asthma is not a risk factor for a severe course of COVID-19

According to the statement of the Czech Initiative for Asthma from April 2020, the disease COVID-19 caused by the new type of coronavirus does not pose significantly greater danger for people with asthma than for the general population. It is, however, necessary to adhere to the prescribed treatment and keep asthma under control. The Journal of Allergy and Clinical Immunology provides an explanation for this surprising phenomenon. It is the reduced expression of ACE2 receptors in people with asthma and allergies, as shown by a new study involving three cohorts of pediatric and adult patients. The SARS-CoV-2 virus uses ACE2 receptors to enter the host cell.
Source: Asthma under control 12. 6. 2020

News How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?

Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2 diabetes mellitus (DM2), examining the cardiovascular risk impact when treated with empagliflozin, liraglutide, or sitagliptin. Currently, there is limited evidence comparing the effectiveness of various glucose-lowering agents intended for second-line treatment in DM2 patients undergoing routine care, who have a broad spectrum of cardiorenal risks.
Source: Diabetes 28. 8. 2023

News Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results

Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for the treatment of ulcerative colitis (UC) in adult patients. We summarize the results of the phase III placebo-controlled True North study published in the New England Journal of Medicine, which demonstrated efficacy and safety in both induction and maintenance therapy for UC.
Source: Modulation of S1P in the Treatment of Autoimmune Diseases 9. 5. 2023

News Management of Musculoskeletal Issues in Hemophiliacs at a Glance

Musculoskeletal issues are among the most common complications of hemophilia. Prevention and early treatment are crucial, and this message is also addressed to specialists by the World Federation of Hemophilia (WFH) guidelines from 2020.
Source: Hemophilia with Movement 17. 5. 2022

News Efficacy of Hyaluronic Acid Eye Drops in the Treatment of Dry Eye Syndrome – Results of a Meta-Analysis

Dry eye syndrome affects 5–30% of individuals over the age of 50. The beneficial effect of hyaluronic acid on the symptoms of this condition has been well described in both preclinical and clinical studies, and it has been shown that its topical application increases the secretion of water and mucin on the surface of the eye. The meta-analysis presented below focused on the efficacy of eye drops containing hyaluronic acid in the treatment of dry eye syndrome.
Source: Ophthalmologic Diseases 13. 3. 2023

News Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention

Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or CV disease fail to reach target LDL-c levels even when given the maximum tolerated dose of conventional hypolipidemic treatment. For these patients, inclisiran—a small interfering RNA (siRNA) that lowers cholesterol—offers hope. In the following article, we present a model example of a patient after an acute coronary event for whom starting inclisiran treatment is appropriate.
Source: Chronic Heart Failure and Lipidology 23. 12. 2022

News Thyroid Disorder Screening in Pregnancy to Be Tested by Pilot Program Starting September

The expectations surrounding the trial launch of the screening program were discussed by Professor Michal Kršek, Chairman of the Czech Endocrinological Society ČLS JEP, on the occasion of the 12th annual “Thyroid Week”.
Source: Thyroid Disorders 8. 6. 2020

News Meta-analysis of the Effectiveness of Romosozumab in the Treatment of Postmenopausal Osteoporosis

Osteoporosis is a prevalent disease with unmet therapeutic needs. Whether the anti-sclerostin antibody romosozumab can offer an effective improvement in osteoporosis treatment outcomes in postmenopausal women was the central question addressed by the meta-analysis presented below.
Source: Osteoporosis – Trends in Sequential Therapy 29. 2. 2024

News Overall Survival and Tolerance of Olaparib in the OlympiAD Study – Results of Extended Follow-up

Olaparib provides women with metastatic breast cancer with a germline BRCA mutation, who have not been pre-treated with chemotherapy, not only with extended progression-free survival but also, according to the latest reports, longer overall survival. Its tolerability is good over the long term.
Source: Ovarian and Breast Cancer 28. 5. 2020

News Albuminuria as a Risk Factor for Cardiovascular Events and Mortality in Patients with Type 2 Diabetes Without Apparent Cardiovascular Disease

Albuminuria in patients with type 2 diabetes is associated with a higher risk of cardiovascular (CV) events and higher mortality. However, this association has not been thoroughly investigated in diabetics without evident atherosclerotic disease. A study with a large cohort of Danish patients helped fill in the missing data.
Source: Diabetes 12. 4. 2022

1 30 31 32 33 34 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#